ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

ClinicalTrials.gov ID: NCT06151574

Public ClinicalTrials.gov record NCT06151574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Study identification

NCT ID
NCT06151574
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
428 participants

Conditions and interventions

Interventions

  • carboplatin Drug
  • cisplatin Drug
  • pembrolizumab Drug
  • pemetrexed Drug
  • zongertinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 8, 2024
Primary completion
Sep 1, 2026
Completion
Jan 27, 2028
Last update posted
Apr 28, 2026

2024 – 2028

United States locations

U.S. sites
22
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Clearview Cancer Institute Huntsville Alabama 35805
Pioneer Research Center - Bullhead City Bullhead City Arizona 86442
Precision NextGen Oncology Beverly Hills California 90212
ClinRé 001-022 (Premier Cancer Care and Infusion Center) Fresno California 93710
OPN Healthcare, Inc. Glendale California 91203
Scripps Green Hospital La Jolla California 92037
Valkyrie Clinical Trials Los Angeles California 90067
Sharp Memorial Hospital San Diego California 92123
St. Louis Cancer Care, LLP Bridgeton Missouri 63044
Oncology Hematology Associates Springfield Missouri 65807
Cancer Care Specialists Reno Nevada 89511
Northwell Health Lake Success New York 11042
Montefiore Medical Center The Bronx New York 10461
Regional Medical Oncology Center Wilson North Carolina 27893
Gabrail Cancer Center Canton Ohio 44718
Carolina Blood and Cancer Care Associates, PA Rock Hill South Carolina 29732
SCRI Oncology Partners Nashville Tennessee 37203
Huntsman Cancer Institute Salt Lake City Utah 84112
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Swedish Cancer Institute Edmonds Washington 98026
Swedish Cancer Institute Issaquah Washington 98029
Swedish Cancer Institute Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 140 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06151574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06151574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →